Ropivacaine hydrochloride monohydrate , ≥98%(HPLC) , 132112-35-7

Synonym(s):
(2S)-N-(2,6-dimethylphenyl)-1-propyl-2-piperidinecarboxamide hydrochloride monohydrate;(S)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide hydrochloride monohydrate;Naropin hydrochloride monohydrate;Ropivacaine hydrochloride monohydrate

CAS NO.：132112-35-7

Empirical Formula: C17H26N2O.ClH.H2O

Molecular Weight: 328.88

MDL number: MFCD02102164

EINECS: 663-286-1

PRODUCT Properties

• Melting point: 267-269°C
• alpha: D20 -7.28° (c = 2 in water)
• storage temp.: 2-8°C
• solubility: H2O: soluble5mg/mL, clear
• form: powder
• color: white to off-white
• optical activity: [α]/D -9 to -12, c = 1 in methanol
• InChIKey: VSHFRHVKMYGBJL-CKUXDGONSA-N

Description and Uses

(–)-Ropivacaine is a potent and reversible blocker of sodium channels in nerve fibers. In vivo, (–)-ropivacaine induces complete impairment of proprioception, motor function, and nociception in the hindleg of rats when 100 μL of an 8 mM solution is injected percutaneously into the sciatic nerve. (–)-Ropivacaine depresses myocardial contractile force in isolated rat hearts less potently than (±)-ropivacaine, as well as (–)- and (±)-bupivacaine . Formulations containing (–)-ropivacaine have been used as local anesthetics during surgery and childbirth.

Ropivacaine hydrochloride monohydrate has been used as an analyte in tandem mass spectrometry and as an amide-based local anaesthetic to test its effect on breast cancer cell methylation.

Safety

• Symbol(GHS): GHS05
• Signal word: Danger
• Hazard statements: H318
• Precautionary statements: P280-P305+P351+P338
• Hazard Codes: T,Xi
• Risk Statements: 26/27/28-41
• Safety Statements: 22-36/37/39-45-39-26
• RIDADR: UN 2811 6.1 / PGIII
• WGK Germany: 3
• HS Code: 2933399090